Glucagon has traditionally been associated with one thing: raising blood glucose.
So it can sound counterintuitive that retatrutide, a molecule being studied for obesity and type 2 diabetes, was deliberately designed to activate the glucagon receptor.
That receptor activity is not an accidental side effect. It is one of the defining features of retatrutide.
Retatrutide, also known as LY3437943, is a single engineered peptide that activates three receptors:
- the glucose-dependent insulinotropic polypeptide receptor, or GIPR
- the glucagon-like peptide-1 receptor, or GLP-1R
- the glucagon receptor, or GCGR
The scientific idea is that GLP-1 and GIP signaling can help reduce energy intake and improve glucose regulation, while glucagon receptor activation may add a second metabolic component through increased energy expenditure and changes in lipid metabolism.
That combination is what makes retatrutide a triple agonist.
But the glucagon part of the mechanism is also the least settled scientifically. Preclinical evidence strongly supports a role for glucagon receptor activation in retatrutide’s weight-loss effects. Human clinical trials show impressive weight and metabolic changes, but they cannot yet tell us precisely how much of those effects comes from the glucagon receptor itself.
TL;DR
Retatrutide activates the glucagon receptor because researchers are trying to combine several complementary metabolic signals in one molecule.
The proposed model is:
GLP-1R activation: reduced appetite and food intake, improved glucose-dependent insulin secretion.
GIPR activation: additional incretin signaling and metabolic effects.
GCGR activation: increased energy expenditure, altered hepatic lipid metabolism, and potentially additional effects on appetite and nutrient handling.
In the original retatrutide discovery experiments, glucagon receptor activity increased weight loss in obese mice by adding an energy-expenditure component to the reduction in calorie intake produced by GIP and GLP-1 receptor activity.
The important limitation is that this mechanistic contribution has been much easier to demonstrate in animals than in humans.
Retatrutide Is a Unimolecular Triple Agonist
Retatrutide is not a mixture of three different hormones.
It is one peptide engineered to activate three related G-protein-coupled receptors.
The original 2022 discovery paper described LY3437943 as a novel glucagon, GIP, and GLP-1 receptor agonist designed to combine the metabolic properties of all three pathways within a single molecule.
This concept is often described as a unimolecular polyagonist.
Instead of administering:
GLP-1 + GIP + glucagon
as three separate compounds, a single engineered peptide carries activity at all three receptor targets.
That matters because the relative strength of receptor activation can be designed into the molecule.
And retatrutide is not equally potent at all three receptors.
Retatrutide Does Not Activate All Three Receptors Equally
Researchers measured retatrutide’s activity using human receptor-expressing cell systems and cAMP signaling assays.
The reported EC50 values were approximately:
| Human receptor | Retatrutide EC50 |
|---|---|
| GIPR | 0.0643 nM |
| GLP-1R | 0.775 nM |
| GCGR | 5.79 nM |
Retatrutide was a full agonist at all three receptors in the functional assays.
Compared with the corresponding natural hormones, the study found that retatrutide was:
- about 8.9 times more potent than native GIP at the human GIP receptor
- about 2.5 times less potent than native GLP-1 at the human GLP-1 receptor
- about 2.9 times less potent than native glucagon at the human glucagon receptor.
So calling retatrutide a “triple agonist” does not mean each receptor receives identical pharmacological stimulation.
Its receptor profile is deliberately unbalanced.
What Does EC50 Mean?
EC50 is the concentration of a compound required to produce 50% of its maximal measured effect in a particular experimental system.
A lower EC50 generally indicates greater potency in that assay.
That is why the GIP receptor number stands out.
Retatrutide requires a much lower concentration to reach half-maximal GIPR signaling than it does at GCGR.
But EC50 values should not be read as a complete map of what happens inside a human body.
Receptor expression differs between tissues. Drug concentration changes over time. Downstream signaling varies. And laboratory cell systems cannot reproduce all of human physiology.
The values are best understood as evidence that retatrutide is pharmacologically active at all three intended targets.
Why Add Glucagon to GLP-1 and GIP?
The logic comes from energy balance.
Body weight is influenced by both:
energy intake
and
energy expenditure.
GLP-1-based therapies are particularly effective at reducing food intake. GLP-1 receptor signaling affects appetite and satiety, which can produce a substantial decrease in energy consumption.
But researchers have long been interested in whether pharmacological obesity treatments could also influence the other side of the equation.
That is where glucagon became interesting.
Although glucagon is best known as a glucose-regulating hormone, it has broader effects on:
- energy expenditure
- lipid oxidation
- hepatic metabolism
- amino-acid metabolism
- food intake.
Reviews of glucagon physiology have documented its ability to increase energy expenditure and influence hepatic lipid metabolism, although the magnitude and mechanisms in humans remain less certain than in animal models.
The Original Retatrutide Experiments Tested This Directly
One of the strongest mechanistic findings came from the preclinical development of LY3437943.
In obese mice, researchers found that the addition of glucagon receptor signaling enhanced the amount of weight lost.
The proposed mechanism included two complementary components:
GIPR and GLP-1R activity reduced calorie intake.
GCGR activity increased energy expenditure.
The discovery paper concluded that glucagon receptor-mediated increases in energy expenditure augmented the body-weight reduction produced through GIP and GLP-1 receptor signaling.
This is an important result because it provides a mechanistic reason for building a triple agonist instead of simply producing another GLP-1/GIP dual agonist.
Glucagon May Affect Energy Expenditure
Glucagon’s effect on energy expenditure is not a new discovery.
Human experiments going back decades have found that glucagon administration can acutely increase oxygen consumption and energy expenditure under some experimental conditions.
A scientific review of the literature found multiple human infusion studies in which glucagon increased energy expenditure, although results varied according to factors such as fasting state, insulin concentrations, and experimental design.
A more recent 2026 review reached a similar conclusion.
Preclinical evidence for glucagon-induced energy expenditure is strong, while the magnitude of the effect in humans appears more modest and context-dependent.
That distinction matters when discussing retatrutide.
We should not assume that an energy-expenditure mechanism demonstrated in obese mice contributes the same proportion of weight loss in humans.
Energy Expenditure Is Only Part of Glucagon Biology
Glucagon receptor activation also changes the way nutrients are processed.
The glucagon receptor is particularly important in the liver.
Glucagon signaling influences:
- glycogen metabolism
- hepatic glucose production
- amino-acid turnover
- fatty-acid oxidation
- hepatic lipid metabolism.
This is one reason glucagon receptor agonism has attracted interest for metabolic diseases associated with excess liver fat. Reviews of GLP-1/glucagon co-agonists have reported reductions in hepatic fat and improvements in lipid-related measures across several experimental compounds.
Retatrutide itself has produced particularly large reductions in liver fat in clinical research, although those changes cannot yet be attributed specifically to its glucagon receptor activity.
Weight loss alone can substantially reduce liver fat.
Doesn’t Glucagon Raise Blood Sugar?
Yes.
And this is the central pharmacological challenge.
Glucagon can stimulate hepatic glucose production.
Taken by itself, strong glucagon receptor agonism could therefore work against the goal of improving hyperglycemia in someone with type 2 diabetes.
That sounds like a major problem for a metabolic drug.
The polyagonist strategy tries to solve that problem by pairing glucagon receptor activation with incretin receptor activation.
GLP-1 and GIP signaling support glucose-dependent insulin secretion and improved glycemic control. GLP-1 also reduces glucagon secretion under hyperglycemic conditions.
A review of clinical GLP-1/glucagon receptor co-agonists found that the potentially hyperglycemic effects of glucagon receptor stimulation can largely be offset when GCGR activity is combined with appropriate GLP-1 receptor activity.
Retatrutide’s clinical results support that broader concept.
Despite activating the glucagon receptor, retatrutide has lowered A1C substantially in people with type 2 diabetes rather than worsening it.
Retatrutide Has Improved Glucose Control in Humans
In the Phase 2 type 2 diabetes trial, higher retatrutide doses reduced A1C by around 2 percentage points while also producing substantial weight loss.
Those findings were later supported by Phase 3 TRANSCEND-T2D-1 results.
So glucagon receptor agonism does not appear to overwhelm the glucose-lowering actions of the complete retatrutide molecule.
This illustrates an important concept in polyagonist pharmacology:
The effect of the entire molecule cannot be predicted by looking at one receptor in isolation.
The receptor balance matters.
Receptor Balance May Be More Important Than Simply Adding More Targets
Triple agonism does not automatically mean “better” than dual agonism.
An effective polyagonist has to activate each receptor in a useful proportion.
Too little glucagon receptor activity might add little to the molecule.
Too much could potentially produce unwanted effects on glucose, heart rate, blood pressure, amino-acid metabolism, or tolerability.
Researchers studying glucagon-based multi-agonists have repeatedly emphasized that the balance between GLP-1 and glucagon receptor activity appears important to both efficacy and safety.
Retatrutide’s receptor profile is therefore part of the molecule’s design rather than a simple checklist of three targets.
Could Glucagon Explain Retatrutide’s Large Weight-Loss Results?
Possibly in part.
But we cannot currently assign a percentage.
In the Phase 2 obesity trial, retatrutide produced average weight loss of about 24.2% at 48 weeks in the 12 mg group. Phase 3 TRIUMPH-1 later reported average reductions as high as 28.3% at 80 weeks under the efficacy estimand.
Those results are consistent with the hypothesis that adding GCGR activity may enhance the effects of GIPR/GLP-1R agonism.
They do not prove it.
The clinical trials compare retatrutide with placebo, not with an otherwise identical retatrutide molecule lacking glucagon receptor activity.
Without that kind of controlled mechanistic comparison in humans, researchers cannot isolate exactly how much of the clinical result is caused by GCGR activation.
Animal Mechanisms Should Not Automatically Be Assumed in Humans
This is especially important with glucagon.
The discovery experiments provide strong evidence that GCGR activation increased energy expenditure and enhanced weight loss in mice.
But recent reviews continue to emphasize that direct mechanistic evidence for the same effect in humans is limited.
A 2025 IUPHAR review noted that much of the mechanistic case for glucagon receptor agonism still rests on preclinical evidence.
And a 2026 review of energy-expenditure studies found mixed results when GLP-1-based therapies were combined with glucagon or GIP in human experiments.
So the careful conclusion is not:
Retatrutide works because glucagon burns more calories.
The scientifically defensible conclusion is:
Glucagon receptor activation was designed to add catabolic and energy-expenditure effects to GIP and GLP-1 signaling, and this mechanism is strongly supported by preclinical experiments. Its quantitative contribution to retatrutide’s effects in humans has not yet been established.
Glucagon May Also Help Explain Effects on Liver Fat
Another area of interest is hepatic metabolism.
Retatrutide has produced very large reductions in liver fat in its MASLD substudy.
Glucagon receptor signaling can increase hepatic lipid oxidation and alter nutrient metabolism, making it biologically plausible that GCGR activity contributes to these changes.
But once again, there are multiple overlapping explanations.
Retatrutide also causes:
- major weight loss
- lower insulin concentrations
- improved insulin sensitivity
- reduced visceral fat
- improved triglycerides.
Each can influence liver fat.
The clinical research therefore cannot yet separate the direct effect of glucagon receptor signaling from the indirect effect of losing substantial body weight.
What the Triple-Agonist Concept Is Really Testing
Retatrutide represents a larger idea in metabolic pharmacology.
Earlier incretin medicines primarily targeted one pathway.
Semaglutide activates GLP-1R.
Tirzepatide activates GIPR and GLP-1R.
Retatrutide adds GCGR to the combination.
The scientific question is whether a carefully engineered single molecule can combine:
appetite suppression
with
glucose regulation
and potentially
greater metabolic energy expenditure and lipid mobilization.
The clinical results show that the molecule can produce substantial metabolic effects.
What researchers are still working out is exactly how the three receptor pathways interact to produce them.
Conclusion
Retatrutide activates the glucagon receptor because glucagon biology extends well beyond raising blood glucose.
GCGR signaling can influence energy expenditure, hepatic lipid metabolism, nutrient handling, and appetite.
In preclinical retatrutide studies, adding glucagon receptor activity increased energy expenditure and enhanced body-weight reduction beyond the effects associated with GIP and GLP-1 signaling.
But human physiology is more complicated.
Retatrutide’s large clinical effects are produced by a molecule acting on all three receptors simultaneously, and current trials cannot tell us exactly how much each receptor contributes.
That makes glucagon receptor activation one of the most interesting parts of retatrutide’s design, but also one of the areas where further mechanistic human research is still needed.
Retatrutide remains investigational and has not yet been approved for medical use.
References
Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022. Read the study
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023. Read the study
Müller TD, et al. Glucagon and energy expenditure; Revisiting amino acid metabolism and implications for weight loss therapy. PubMed record
Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity. PubMed record